Rapid. Scalable. Accessible. Microbial Platforms for the World.
At Mika Biologics, we believe vaccines are not just products—they are global infrastructure for human health. Few technologies have saved more lives. Yet the world still faces massive inequities: vaccines that are too costly, too fragile, too slow to produce, or too centralized in their manufacturing.
Mika Biologics exists to change that. Our microbial-first CDMO platform specializes in vaccine scaffolds, VLPs (virus-like particles), microbial nanostructures, and rapid-response microbial systems. We deliver biologics that are faster, cheaper, and more scalable than mammalian systems—making them ideal for pandemic readiness, oncology vaccines, and global health programs.
We don’t just see ourselves as a CDMO. We see ourselves as a partner in global health security, helping innovators build vaccines and therapeutics that can reach every corner of the world.
We are the best microbial & phage vaccine CDMO in the U.S., the world, and the galaxy.
What Global Health Innovators Value
Vaccine developers, NGOs, and global health organizations face unique constraints. What they value in CDMO partners:
1. Speed to Scale
During pandemics or outbreaks, speed is everything. Microbial platforms enable rapid antigen pivoting and scalable fermentation.
2. Cost Efficiency
For vaccines destined for low-resource settings, cost per dose matters. Microbial fermentation yields lower COGs than mammalian or egg-based systems.
3. Stability & Distribution
Global programs require vaccines that can withstand fragile cold chains. Microbial and nanoparticle scaffolds offer greater stability, freeze-drying compatibility, and robustness.
4. Platform Versatility
Global health groups need modular platforms: plug-and-play VLP scaffolds, microbial vaccines, nanoparticles, and probiotics that can be adapted quickly.
5. Regulatory & Logistics Support
Global programs often need multi-region regulatory alignment (FDA, EMA, WHO PQ). They also value logistics partnerships for worldwide distribution.
6. Niche & Orphan Pathogen Support
Diseases overlooked by large pharma still devastate communities. Global health partners need CDMOs willing to work on low-volume but high-impact vaccines.
Current Technical Needs in Vaccines & Global Health
- Virus-Like Particles (VLPs)
- Safe, non-replicating immunogenic scaffolds.
- Used in oncology vaccines, pandemic response, and infectious disease.
- Microbial Vaccine Platforms
- E. coli, yeast, and fungal systems producing antigens, scaffolds, and nanoparticles.
- Rapid pivoting for outbreak pathogens.
- Nanoparticles & Scaffolds
- Self-assembling protein nanoparticles for antigen delivery.
- Robust stability and modular antigen display.
- Engineered Probiotics
- Probiotic strains delivering mucosal vaccines or immune modulators.
- Endotoxin-Free Vaccine Components
- Plasmids, cytokines, and proteins produced in ClearColi® or engineered strains.
- GMP Rapid Response
- Ability to scale from lab → GMP supply in weeks.
- Global Access-Oriented Manufacturing
- Cost-effective processes, lyophilized formats, WHO PQ readiness.
Innovation in Vaccines & Global Health Today
Mika’s expertise aligns directly with innovation trends:
- Oncology Vaccines – VLPs presenting tumor antigens.
- Pandemic-Ready Platforms – microbial scaffolds pivoting within weeks to new sequences.
- Protein Nanoparticles – self-assembling antigen carriers with strong immunogenicity.
- CRISPR-Based Diagnostics & Vaccines – CRISPR tools integrated with global health platforms.
- Engineered Probiotics – living vaccines delivered orally or mucosally.
- Distributed Biomanufacturing – small-footprint systems enabling regional vaccine supply.
- Thermal Stability Engineering – vaccines formulated for shelf stability without cold chains.
How Mika Delivers Value to Vaccines & Global Health
1. Microbial-First Platforms
We specialize in E. coli, yeast, fungi, and phages, delivering scalable antigen/VLP/nanoparticle systems.
2. Pandemic-Scale Agility
Our systems pivot rapidly from new sequence → antigen → VLP assembly → GMP scale.
3. Lower Costs, Greater Reach
Microbial fermentation reduces COGs, making vaccines more globally accessible.
4. Regulatory Fluency
We support IND/CTA filings, WHO PQ pathways, and multi-region regulatory alignment.
5. Global Health Partnerships
We collaborate with NGOs, public–private consortia, and pharma to deliver vaccines that reach beyond the wealthy few.
Technical Capabilities That Matter to Vaccine Developers
- Fermentation: 1–2000 L microbial, expandable to 20,000 L with partners.
- Downstream: ultracentrifugation, chromatography, TFF, lyophilization.
- Analytics: EM, DLS, immunoassays, neutralization tests.
- Formulation: freeze-drying, adjuvant integration, room-temperature stability.
- Quality Systems: GMP, FDA/EMA compliance, WHO PQ support.
Case Examples
- Oncology Biotech – cancer vaccine scaffold produced in yeast, scaled to GMP.
- Global Health NGO – microbial vaccine against outbreak pathogen, scaled from gene to GMP in under 8 weeks.
- Diagnostics Company – CRISPR-based antigen test produced endotoxin-free.
- Public–Private Partnership – nanoparticle vaccine developed for global distribution with lyophilized stability.
Top 10 Technical FAQs for Vaccines & Global Health
1. What microbial systems does Mika use for vaccines?
E. coli, yeast (Pichia, Saccharomyces), fungi (Aspergillus), phages (M13/f1 scaffolds).
2. Can Mika produce VLPs at GMP scale?
Yes—1–2000 L microbial fermentation, validated assembly, and GMP production.
3. How fast can Mika pivot to new antigens?
Weeks, not months. Cell-free + microbial platforms allow rapid antigen prototyping.
4. What about stability for global distribution?
We provide lyophilized formulations and adjuvant integration for room-temperature stability.
5. Does Mika support oncology vaccines?
Yes—VLPs and nanoparticle scaffolds designed for tumor antigens.
6. Can Mika handle endotoxin-free vaccines?
Yes—ClearColi® strains and engineered hosts for clean plasmids and proteins.
7. How does Mika handle global regulatory needs?
IND/CTA filing support, WHO PQ guidance, multi-region regulatory alignment.
8. Can Mika support pandemic-scale production?
Yes—rapid scale-up, partner capacity up to 20,000 L, global logistics support.
9. What about engineered probiotics as vaccines?
Yes—we develop probiotic LBPs delivering mucosal vaccines or immune ligands.
10. Why Mika for global health vs. large CDMOs?
We combine speed, cost-efficiency, and microbial-first specialization—with focus on accessibility, not just blockbuster margins.
The Future of Vaccines & Global Health with Mika
We see vaccines not as seasonal products but as permanent global infrastructure. Our roadmap includes:
- Designer VLP Libraries – plug-and-play antigen scaffolds.
- AI-Optimized Nanoparticles – predictive models for immunogenic assembly.
- Distributed Microbial Biomanufacturing – portable fermentors for regional supply.
- Cross-Platform Integration – probiotics, nanoparticles, and VLPs combined into hybrid vaccines.
- Global Equity in Biologics – microbial-first systems making advanced biologics affordable worldwide.
Closing Statement
Vaccines are more than biologics—they are lifelines. Global health demands platforms that are faster, cheaper, safer, and more accessible.
At Mika Biologics, we deliver microbial-first vaccine and nanoparticle systems designed for pandemic readiness, oncology, and rare infectious diseases. With GMP-grade expertise, regulatory fluency, and global partnerships, we are the best microbial vaccine CDMO in the U.S., the world, and the galaxy. We don’t just manufacture vaccines—we help build health security for all.
Mika Biologics. Microbial Systems. Immune Innovation. Beyond the Cell.
Contact our team
@ info@mikabiologics.com
We are ready to talk!
